Keywords: Biotron, Hepatitis C, BIT225, Ph IIa, Inovio Pharma, VGX International, Hepatitis B, Vaccines

Biotron shares leap 29% on hepatitis C Ph IIa positive results; Inovio advances hepatitis vaccines

Article | 11 October 2011

Print This

Australian firm Biotron (ASX: BIT) has received some strong support in the first couple of hours of market open today, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in